STAT23h
Denali Therapeutics spinout raises $200M as neuro company resets
Tenvie Therapeutics is making hay from an R&D shift at Denali Therapeutics, acquiring several of its neuroscience drug ...
FierceBiotech1d
Arch-backed Tenvie unveils with $200M and a neuro pipeline with assets from Denali
Tenvie Therapeutics has unveiled with $200 million and the goal of transforming the neurological treatment landscape, nabbing ...
BioSpace21h
Tenvie Debuts With Denali Assets, $200M for Neurological, Metabolic Diseases
Backed by ARCH Venture Partners, F-Prime Capital and Mubadala Capital, the new company will develop a pipeline of ...
Tenvie Therapeutics Launches with $200 Million to Deliver Breakthrough Small Molecule Therapies
Advancing a deep pipeline of therapeutics focused on treating neurological, cardiometabolic, and ophthalmic diseasesLed by expert R&D ...
FierceBiotech28d
Tenpoint, Visus merge in effort to push presbyopia-correcting eye drop over FDA finish line
The deal has triggered a crossover financing round with participation from numerous investors, including F-Prime Capital and Sofinnova Partners—both former backers of Tenpoint. The combined ...
The Victoria Advocate21d
TripSuite Secures $5 Million to Revolutionize the Way Travel Agencies Operate
The round was led by F-Prime Capital, with participation from Bienville Capital Management and Thayer Ventures. The investment will further TripSuite's mission to enhance the agency and traveler ...
Pharmaceutical Technology3d
Muzastotug by Adagene Suzhou for Solid Tumor: Likelihood of Approval
Muzastotug is under clinical development by Adagene Suzhou and currently in Phase II for Solid Tumor. According to GlobalData, Phase II drugs for Solid Tumor have a 37% phase transition success rate ...